"N Engl J Med"[journal] 检索结果

1321. Judicial Invalidation of the FDA's Laboratory-Developed Test Rule - Legal and Public Health Consequences.

作者: Rachel E Sachs.;Joshua M Sharfstein.;Patricia J Zettler.
来源: N Engl J Med. 2025年392卷20期e49页

1322. More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.

作者: Yoshitomo Hoshino.;Kazuo Okamoto.;Nobuaki Ito.
来源: N Engl J Med. 2025年392卷18期1871-1872页

1323. More on Acquired Osteomalacia and Autoantibodies against PHEX.

作者: Salvatore Minisola.;Jessica Pepe.;Cristiana Cipriani.
来源: N Engl J Med. 2025年392卷18期1871页

1324. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Reply.

作者: Marianna Fontana.;Ronald M Witteles.;Satish A Eraly.
来源: N Engl J Med. 2025年392卷18期1870-1871页

1325. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

作者: Mohamad Zaidan.
来源: N Engl J Med. 2025年392卷18期1870页

1326. Cabozantinib in Advanced Neuroendocrine Tumors. Reply.

作者: Jennifer A Chan.;Susan Geyer.;Jeffrey A Meyerhardt.
来源: N Engl J Med. 2025年392卷18期1869-1870页

1327. Cabozantinib in Advanced Neuroendocrine Tumors.

作者: Diamantis I Tsilimigras.
来源: N Engl J Med. 2025年392卷18期1869页

1328. Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.

作者: Claudia K Fox.;Nina M Harder-Lauridsen.;Silva Arslanian.
来源: N Engl J Med. 2025年392卷18期1868页

1329. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Josephine M Egan.;Dimitrios Kapogiannis.
来源: N Engl J Med. 2025年392卷18期1866-1868页

1330. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Conghua Ji.;Minyan Wang.
来源: N Engl J Med. 2025年392卷18期1867页

1331. Liraglutide for Children 6 to <12 Years of Age with Obesity.

作者: Saul Malozowski.
来源: N Engl J Med. 2025年392卷18期1866-1867页

1332. Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.

作者: Franziska Scheibe.;Julia Melchert.;Helena Radbruch.;Eberhard Siebert.;Till D Best.;Siegfried Kohler.;Mira Fitzek.;Alexander Kowski.;Volker Siffrin.;Jenny Meinhardt.;Raphael Raspe.;Viktor Horst.;Bianca Zukunft.;Klemens Budde.;Frank K H van Landeghem.;Christopher Power.;Kai-Uwe Eckardt.;Matthias Endres.;Christian Drosten.;Victor M Corman.;Klemens Ruprecht.
来源: N Engl J Med. 2025年392卷18期1864-1866页

1333. Automated Insulin Pump in Type 2 Diabetes.

作者: Betul Hatipoglu.
来源: N Engl J Med. 2025年392卷18期1862-1863页

1334. To BCG or Not Two BCG.

作者: Stephen M Carpenter.;W Henry Boom.
来源: N Engl J Med. 2025年392卷18期1860-1862页

1335. Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma.

作者: Francesco Maura.;P Leif Bergsagel.
来源: N Engl J Med. 2025年392卷18期1858-1860页

1336. Case 13-2025: A 70-Year-Old Man with Weight Loss, Weakness, and Anorexia.

作者: Matthew G Gartland.;Samuel C D Cartmell.;John S Albin.;Daniel Restrepo.;Anthony R Russo.
来源: N Engl J Med. 2025年392卷18期1847-1856页

1337. Sea Anemone Sting.

作者: Weniko Caré.;Raphaële Mestiri.
来源: N Engl J Med. 2025年392卷18期e43页

1338. Chemical Complexity of Food and Implications for Therapeutics.

作者: Giulia Menichetti.;Albert-László Barabási.;Joseph Loscalzo.
来源: N Engl J Med. 2025年392卷18期1836-1845页

1339. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.

作者: Jakub Svoboda.;Daniel J Landsburg.;James Gerson.;Sunita D Nasta.;Stefan K Barta.;Elise A Chong.;Michael Cook.;Noelle V Frey.;Joanne Shea.;Amanda Cervini.;Amy Marshall.;Megan Four.;Megan M Davis.;Julie K Jadlowsky.;Anne Chew.;Edward Pequignot.;Vanessa Gonzalez.;Julia Han Noll.;Luca Paruzzo.;Juliana Rojas-Levine.;Gabriela Plesa.;John Scholler.;Donald L Siegel.;Bruce L Levine.;David L Porter.;Saba Ghassemi.;Marco Ruella.;Andrew Rech.;Rachel M Leskowitz.;Joseph A Fraietta.;Wei-Ting Hwang.;Elizabeth Hexner.;Stephen J Schuster.;Carl H June.
来源: N Engl J Med. 2025年392卷18期1824-1835页

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity.

1340. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.

作者: Alexander C Schmidt.;Lee Fairlie.;Elizabeth Hellström.;Angelique Luabeya Kany Kany.;Keren Middelkoop.;Kogieleum Naidoo.;Gonasagrie Nair.;Anele Gela.;Elisa Nemes.;Thomas J Scriba.;Amy Cinar.;Nicole Frahm.;Robin Mogg.;David Kaufman.;Michael W Dunne.;Mark Hatherill.; .
来源: N Engl J Med. 2025年392卷18期1789-1800页

In a previous phase 2 trial, bacille Calmette-Guérin (BCG) revaccination was not shown to provide protection from primary Mycobacterium tuberculosis infection but prevented sustained M. tuberculosis infection, defined by an initial conversion on a QuantiFERON-TB (QFT) test (an interferon-γ release assay) from negative to positive, followed by two additional positive QFT tests at 3 and 6 months after the initial conversion (a secondary end point). A vaccine efficacy of 45% (95% confidence interval [CI], 6 to 68) was observed.

结果排序

文献格式

出版时间

出版类型

出版语言